Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717905) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)' on July 16.

Brief Summary: This is a Phase IIa, randomized, blinded, placebo controlled,Multiple-Ascending Dose study of BBT001 in adult patients with Chronic Spontaneous Urticaria.

Study Start Date: June 29

Study Type: INTERVENTIONAL

Condition: Chronic Spontaneous Urticaria

Intervention: DRUG: BBT001

BBT001 will be administered

DRUG: Placebo

Placebo will be administered

Recruitment Status: RECRUITING ...